BioStock: PHI aims for US listing

July 11, 2024
Language flag

Swedish Medtech Phase Holographic Imaging is making significant strides in the United States, establishing itself at the forefront of the rapidly growing regenerative medicine field. PHI is now taking an important step by applying for listing its shares in the US OTCQB market to enhance its presence and opportunities in the US. BioStock talked to CEO Patrik Eschricht to learn more about what this means for the company.

Read the full interview with Patrik Eschricht on biostock.se.

We are very happy about the possibility of dual-listing on the OTCQB, which would be another significant step in PHI’s growth journey as a global company. This dual listing would make it more accessible for international investors to invest in PHI, positively increasing liquidity, boosting shareholder value, and supporting our ongoing growth.

Further reading

PHI CSO Kersti Alm at Biostock

BioStock: PHI on the alliance for cell-based biomanufacturing

Kersti Alm, CSO at PHI, visited BioStock’s studio to talk about the recently created alliance for advancing cell-based biomanufacturing and PHI’s pivotal role in the collaboration.
PHI part of new regenerative medicine alliance

BioStock: PHI part of new regenerative medicine alliance

BioStock contacted Product Manager Lisa Lindström to learn more about PHI’s newly formed technology development alliance for regenerative medicine and what excites her about the future.
Biostock-regenerative-medicine-phi

BioStock: PHI expands market potential with regenerative medicine opportunity

BioStock contacted CFO Patrik Eschricht to find out more about PHI’s visions regarding regenerative medicine, cell-based therapies and automatization of biomanufacturing.
fill or kill podcast

PHI som gäst i Fill or Kill podcast: Avsnitt 366

Lyssna på Fill or Kill intervjun med PHI vd Peter Egelberg.
1…678910

Latest News

PHI AB’s warrant exercise registered at the Swedish Companies Registration Office

Phase Holographic Imaging PHI AB (“PHI” or “Company”) today announces that the new shares from the exercise of warrants of series TO 4 have been registered at the Swedish Companies Registration Office.
Phase Holographic Imaging logotype with company name

PHI appoints Anders Månsson as new CEO

The board of Phase Holographic Imaging (PHI) has today appointed Anders Månsson as the new CEO of PHI as of November 1, 2024. The current CEO, Patrik Eschricht, will remain in his role until November 1, 2024, and ensure a smooth handover to Anders Månsson.

Phase Holographic Imaging PHI AB receives approx. SEK 5.2 million through warrant exercise

On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s (“PHI” or the “Company”) rights issue of units in 2022 (“TO 4”), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.
See All News